wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q38404422-330397AB-1D6C-41A6-BADA-D6FBDCCBC9B7
Q38404422-330397AB-1D6C-41A6-BADA-D6FBDCCBC9B7
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38404422-330397AB-1D6C-41A6-BADA-D6FBDCCBC9B7
Which tyrosine-kinase inhibitor to use first in chronic phase chronic myelogenous leukemia?
P2860
Q38404422-330397AB-1D6C-41A6-BADA-D6FBDCCBC9B7
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38404422-330397AB-1D6C-41A6-BADA-D6FBDCCBC9B7
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
38c4135fe57d9f81540a31d707b3606ba694db31
P2860
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).